Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

ACS medicinal chemistry letters

Balog A, Rampulla R, Martin GS, Krystek SR, Attar R, Dell-John J, DiMarco JD, Fairfax D, Gougoutas J, Holst CL, Nation A, Rizzo C, Rossiter LM, Schweizer L, Shan W, Spergel S, Spires T, Cornelius G, Gottardis M, Trainor G, Vite GD, Salvati ME.
PMID: 26288692
ACS Med Chem Lett. 2015 Jun 19;6(8):908-12. doi: 10.1021/acsmedchemlett.5b00173. eCollection 2015 Aug 13.

BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human...

Cite
Balog A, Rampulla R, Martin GS, et al. Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. ACS Med Chem Lett. 2015;6(8):908-12doi: 10.1021/acsmedchemlett.5b00173.
Balog, A., Rampulla, R., Martin, G. S., Krystek, S. R., Attar, R., Dell-John, J., DiMarco, J. D., Fairfax, D., Gougoutas, J., Holst, C. L., Nation, A., Rizzo, C., Rossiter, L. M., Schweizer, L., Shan, W., Spergel, S., Spires, T., Cornelius, G., Gottardis, M., Trainor, G., Vite, G. D., & Salvati, M. E. (2015). Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. ACS medicinal chemistry letters, 6(8), 908-12. https://doi.org/10.1021/acsmedchemlett.5b00173
Balog, Aaron, et al. "Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer." ACS medicinal chemistry letters vol. 6,8 (2015): 908-12. doi: https://doi.org/10.1021/acsmedchemlett.5b00173
Balog A, Rampulla R, Martin GS, Krystek SR, Attar R, Dell-John J, DiMarco JD, Fairfax D, Gougoutas J, Holst CL, Nation A, Rizzo C, Rossiter LM, Schweizer L, Shan W, Spergel S, Spires T, Cornelius G, Gottardis M, Trainor G, Vite GD, Salvati ME. Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. ACS Med Chem Lett. 2015 Jun 19;6(8):908-12. doi: 10.1021/acsmedchemlett.5b00173. eCollection 2015 Aug 13. PMID: 26288692; PMCID: PMC4538445.
Copy Download .nbib Format: NLM
Rotavirus infections in Detroit, USA, a region of low vaccine prevalence.

Virusdisease

Abdel-Haq N, Amjad M, McGrath E, Salimnia H, Fairfax M, Asmar BI.
PMID: 27366769
Virusdisease. 2016 Jun;27(2):179-82. doi: 10.1007/s13337-016-0309-9. Epub 2016 Mar 22.

After a sharp drop of rotavirus (RV) infections at Children's Hospital of Michigan, Detroit, USA in 2010 season, we noted an increase in the number of cases during the 2011 season including some RV vaccine (RVV) recipients. This study...

Cite
Abdel-Haq N, Amjad M, McGrath E, et al. Rotavirus infections in Detroit, USA, a region of low vaccine prevalence. Virusdisease. 2016;27(2):179-82doi: 10.1007/s13337-016-0309-9.
Abdel-Haq, N., Amjad, M., McGrath, E., Salimnia, H., Fairfax, M., & Asmar, B. I. (2016). Rotavirus infections in Detroit, USA, a region of low vaccine prevalence. Virusdisease, 27(2), 179-82. https://doi.org/10.1007/s13337-016-0309-9
Abdel-Haq, Nahed, et al. "Rotavirus infections in Detroit, USA, a region of low vaccine prevalence." Virusdisease vol. 27,2 (2016): 179-82. doi: https://doi.org/10.1007/s13337-016-0309-9
Abdel-Haq N, Amjad M, McGrath E, Salimnia H, Fairfax M, Asmar BI. Rotavirus infections in Detroit, USA, a region of low vaccine prevalence. Virusdisease. 2016 Jun;27(2):179-82. doi: 10.1007/s13337-016-0309-9. Epub 2016 Mar 22. PMID: 27366769; PMCID: PMC4909006.
Copy Download .nbib Format: NLM
Developing an assessment tool for evaluating community involvement.

Health expectations : an international journal of public participation in health care and health policy

South J, Fairfax P, Green E.
PMID: 15713172
Health Expect. 2005 Mar;8(1):64-73. doi: 10.1111/j.1369-7625.2004.00313.x.

BACKGROUND: Current UK policy has resulted in greater requirements for public and patient participation in health service planning and decision making. Organizations and services need to be able to monitor and evaluate the effectiveness and quality of their community...

Cite
South J, Fairfax P, Green E. Developing an assessment tool for evaluating community involvement. Health Expect. 2005;8(1):64-73doi: 10.1111/j.1369-7625.2004.00313.x.
South, J., Fairfax, P., & Green, E. (2005). Developing an assessment tool for evaluating community involvement. Health expectations : an international journal of public participation in health care and health policy, 8(1), 64-73. https://doi.org/10.1111/j.1369-7625.2004.00313.x
South, Jane, et al. "Developing an assessment tool for evaluating community involvement." Health expectations : an international journal of public participation in health care and health policy vol. 8,1 (2005): 64-73. doi: https://doi.org/10.1111/j.1369-7625.2004.00313.x
South J, Fairfax P, Green E. Developing an assessment tool for evaluating community involvement. Health Expect. 2005 Mar;8(1):64-73. doi: 10.1111/j.1369-7625.2004.00313.x. PMID: 15713172; PMCID: PMC5060273.
Copy Download .nbib Format: NLM
Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma.

Expert review of vaccines

Klein-González N, Holtick U, Fairfax K, Weihrauch MR, von Bergwelt-Baildon MS.
PMID: 21434797
Expert Rev Vaccines. 2011 Mar;10(3):295-8. doi: 10.1586/erv.11.6.

Evaluation of: Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010). Despite high response rates of the follicular B-cell...

Cite
Klein-González N, Holtick U, Fairfax K, et al. Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma. Expert Rev Vaccines. 2011;10(3):295-8doi: 10.1586/erv.11.6.
Klein-González, N., Holtick, U., Fairfax, K., Weihrauch, M. R., & von Bergwelt-Baildon, M. S. (2011). Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma. Expert review of vaccines, 10(3), 295-8. https://doi.org/10.1586/erv.11.6
Klein-González, Nela, et al. "Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma." Expert review of vaccines vol. 10,3 (2011): 295-8. doi: https://doi.org/10.1586/erv.11.6
Klein-González N, Holtick U, Fairfax K, Weihrauch MR, von Bergwelt-Baildon MS. Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma. Expert Rev Vaccines. 2011 Mar;10(3):295-8. doi: 10.1586/erv.11.6. PMID: 21434797.
Copy Download .nbib Format: NLM
An immunodominant NP.

Nature immunology

Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, Liu G, Yin Z, Chen JL, Lu Y, Wellington D, Wing PAC, Dominey-Foy DCC, Jin C, Wang W, Hamid MA, Fernandes RA, Wang B, Fries A, Zhuang X, Ashley N, Rostron T, Waugh C, Sopp P, Hublitz P, Beveridge R, Tan TK, Dold C, Kwok AJ, Rich-Griffin C, Dejnirattisa W, Liu C, Kurupati P, Nassiri I, Watson RA, Tong O, Taylor CA, Kumar Sharma P, Sun B, Curion F, Revale S, Garner LC, Jansen K, Ferreira RC, Attar M, Fry JW, Russell RA, Stauss HJ, James W, Townsend A, Ho LP, Klenerman P, Mongkolsapaya J, Screaton GR, Dendrou C, Sansom SN, Bashford-Rogers R, Chain B, Smith GL, McKeating JA, Fairfax BP, Bowness P, McMichael AJ, Ogg G, Knight JC, Dong T.
PMID: 34853448
Nat Immunol. 2022 Jan;23(1):50-61. doi: 10.1038/s41590-021-01084-z. Epub 2021 Dec 01.

NP

Cite
Peng Y, Felce SL, Dong D, et al. An immunodominant NP. Nat Immunol. 2021;23(1):50-61doi: 10.1038/s41590-021-01084-z.
Peng, Y., Felce, S. L., Dong, D., Penkava, F., Mentzer, A. J., Yao, X., Liu, G., Yin, Z., Chen, J. L., Lu, Y., Wellington, D., Wing, P. A. C., Dominey-Foy, D. C. C., Jin, C., Wang, W., Hamid, M. A., Fernandes, R. A., Wang, B., Fries, A., Zhuang, X., Ashley, N., Rostron, T., Waugh, C., Sopp, P., Hublitz, P., Beveridge, R., Tan, T. K., Dold, C., Kwok, A. J., Rich-Griffin, C., Dejnirattisa, W., Liu, C., Kurupati, P., Nassiri, I., Watson, R. A., Tong, O., Taylor, C. A., Kumar Sharma, P., Sun, B., Curion, F., Revale, S., Garner, L. C., Jansen, K., Ferreira, R. C., Attar, M., Fry, J. W., Russell, R. A., Stauss, H. J., James, W., Townsend, A., Ho, L. P., Klenerman, P., Mongkolsapaya, J., Screaton, G. R., Dendrou, C., Sansom, S. N., Bashford-Rogers, R., Chain, B., Smith, G. L., McKeating, J. A., Fairfax, B. P., Bowness, P., McMichael, A. J., Ogg, G., Knight, J. C., & Dong, T. (2022). An immunodominant NP. Nature immunology, 23(1), 50-61. https://doi.org/10.1038/s41590-021-01084-z
Peng, Yanchun, et al. "An immunodominant NP." Nature immunology vol. 23,1 (2022): 50-61. doi: https://doi.org/10.1038/s41590-021-01084-z
Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, Liu G, Yin Z, Chen JL, Lu Y, Wellington D, Wing PAC, Dominey-Foy DCC, Jin C, Wang W, Hamid MA, Fernandes RA, Wang B, Fries A, Zhuang X, Ashley N, Rostron T, Waugh C, Sopp P, Hublitz P, Beveridge R, Tan TK, Dold C, Kwok AJ, Rich-Griffin C, Dejnirattisa W, Liu C, Kurupati P, Nassiri I, Watson RA, Tong O, Taylor CA, Kumar Sharma P, Sun B, Curion F, Revale S, Garner LC, Jansen K, Ferreira RC, Attar M, Fry JW, Russell RA, Stauss HJ, James W, Townsend A, Ho LP, Klenerman P, Mongkolsapaya J, Screaton GR, Dendrou C, Sansom SN, Bashford-Rogers R, Chain B, Smith GL, McKeating JA, Fairfax BP, Bowness P, McMichael AJ, Ogg G, Knight JC, Dong T. An immunodominant NP. Nat Immunol. 2022 Jan;23(1):50-61. doi: 10.1038/s41590-021-01084-z. Epub 2021 Dec 01. PMID: 34853448; PMCID: PMC8709787.
Copy Download .nbib Format: NLM
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.

Scientific reports

Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP.
PMID: 34584157
Sci Rep. 2021 Sep 28;11(1):19253. doi: 10.1038/s41598-021-98700-7.

Development of anti-drug antibodies (ADAs) can interfere with therapeutic monoclonal antibodies and may lead to drug neutralisation and clinical disease progression. Measurement of circulating drug levels and development of ADAs in the setting of anti-programmed cell death-1 agent pembrolizumab...

Cite
Sasson SC, Wilkins LE, Watson RA, et al. Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma. Sci Rep. 2021;11(1):19253doi: 10.1038/s41598-021-98700-7.
Sasson, S. C., Wilkins, L. E., Watson, R. A., Jolly, C., Brain, O., Klenerman, P., Olsson-Brown, A., & Fairfax, B. P. (2021). Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma. Scientific reports, 11(1), 19253. https://doi.org/10.1038/s41598-021-98700-7
Sasson, S C, et al. "Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma." Scientific reports vol. 11,1 (2021): 19253. doi: https://doi.org/10.1038/s41598-021-98700-7
Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP. Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma. Sci Rep. 2021 Sep 28;11(1):19253. doi: 10.1038/s41598-021-98700-7. PMID: 34584157; PMCID: PMC8478874.
Copy Download .nbib Format: NLM
A Systematic Approach to Comparing Thermal Activity of the Thoracic Region and Saddle Pressure Distribution beneath the Saddle in a Group of Non-Lame Sports Horses.

Animals : an open access journal from MDPI

MacKechnie-Guire R, Fisher M, Mathie H, Kuczynska K, Fairfax V, Fisher D, Pfau T.
PMID: 33924326
Animals (Basel). 2021 Apr 13;11(4). doi: 10.3390/ani11041105.

Thermography is a non-invasive method for measuring surface temperatures and may be a convenient way of identifying hypo/hyperthermic areas under a saddle that may be related to saddle pressures. A thermal camera quantified minimum/maximum/mean temperatures at specific locations (left/right)...

Cite
MacKechnie-Guire R, Fisher M, Mathie H, et al. A Systematic Approach to Comparing Thermal Activity of the Thoracic Region and Saddle Pressure Distribution beneath the Saddle in a Group of Non-Lame Sports Horses. Animals (Basel). 2021;11(4)doi: 10.3390/ani11041105.
MacKechnie-Guire, R., Fisher, M., Mathie, H., Kuczynska, K., Fairfax, V., Fisher, D., & Pfau, T. (2021). A Systematic Approach to Comparing Thermal Activity of the Thoracic Region and Saddle Pressure Distribution beneath the Saddle in a Group of Non-Lame Sports Horses. Animals : an open access journal from MDPI, 11(4), . https://doi.org/10.3390/ani11041105
MacKechnie-Guire, Russell, et al. "A Systematic Approach to Comparing Thermal Activity of the Thoracic Region and Saddle Pressure Distribution beneath the Saddle in a Group of Non-Lame Sports Horses." Animals : an open access journal from MDPI vol. 11,4 (2021). doi: https://doi.org/10.3390/ani11041105
MacKechnie-Guire R, Fisher M, Mathie H, Kuczynska K, Fairfax V, Fisher D, Pfau T. A Systematic Approach to Comparing Thermal Activity of the Thoracic Region and Saddle Pressure Distribution beneath the Saddle in a Group of Non-Lame Sports Horses. Animals (Basel). 2021 Apr 13;11(4). doi: 10.3390/ani11041105. PMID: 33924326; PMCID: PMC8068952.
Copy Download .nbib Format: NLM
Toward a better understanding of T cells in cancer.

Cancer cell

Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O.
PMID: 34906313
Cancer Cell. 2021 Dec 13;39(12):1549-1552. doi: 10.1016/j.ccell.2021.11.010.

T cells mediate anti-tumor immune responses and are the key target of immune checkpoint therapy, but they can also promote immune tolerance. A clear understanding of the specific contributions and biology of different T cell subsets is required to...

Cite
Oh DY, Fong L, Newell EW, et al. Toward a better understanding of T cells in cancer. Cancer Cell. 2021;39(12):1549-1552doi: 10.1016/j.ccell.2021.11.010.
Oh, D. Y., Fong, L., Newell, E. W., Turk, M. J., Chi, H., Chang, H. Y., Satpathy, A. T., Fairfax, B., Silva-Santos, B., & Lantz, O. (2021). Toward a better understanding of T cells in cancer. Cancer cell, 39(12), 1549-1552. https://doi.org/10.1016/j.ccell.2021.11.010
Oh, David Y, et al. "Toward a better understanding of T cells in cancer." Cancer cell vol. 39,12 (2021): 1549-1552. doi: https://doi.org/10.1016/j.ccell.2021.11.010
Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O. Toward a better understanding of T cells in cancer. Cancer Cell. 2021 Dec 13;39(12):1549-1552. doi: 10.1016/j.ccell.2021.11.010. PMID: 34906313.
Copy Download .nbib Format: NLM
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8.

Science immunology

Watson RA, Tong O, Cooper R, Taylor CA, Sharma PK, de Los Aires AV, Mahé EA, Ruffieux H, Nassiri I, Middleton MR, Fairfax BP.
PMID: 34597125
Sci Immunol. 2021 Oct;6(64):eabj8825. doi: 10.1126/sciimmunol.abj8825. Epub 2021 Oct 01.

[Figure: see text].

Cite
Watson RA, Tong O, Cooper R, et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8. Sci Immunol. 2021;6(64):eabj8825doi: 10.1126/sciimmunol.abj8825.
Watson, R. A., Tong, O., Cooper, R., Taylor, C. A., Sharma, P. K., de Los Aires, A. V., Mahé, E. A., Ruffieux, H., Nassiri, I., Middleton, M. R., & Fairfax, B. P. (2021). Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8. Science immunology, 6(64), eabj8825. https://doi.org/10.1126/sciimmunol.abj8825
Watson, Robert A, et al. "Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8." Science immunology vol. 6,64 (2021): eabj8825. doi: https://doi.org/10.1126/sciimmunol.abj8825
Watson RA, Tong O, Cooper R, Taylor CA, Sharma PK, de Los Aires AV, Mahé EA, Ruffieux H, Nassiri I, Middleton MR, Fairfax BP. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8. Sci Immunol. 2021 Oct;6(64):eabj8825. doi: 10.1126/sciimmunol.abj8825. Epub 2021 Oct 01. PMID: 34597125.
Copy Download .nbib Format: NLM
The Effectiveness of NEPA.

Science (New York, N.Y.)

Fairfax SK.
PMID: 17777941
Science. 1978 Dec 08;202(4372):1038-41. doi: 10.1126/science.202.4372.1038.

No abstract available.

Cite
Fairfax SK. The Effectiveness of NEPA. Science. 1978;202(4372):1038-41doi: 10.1126/science.202.4372.1038.
Fairfax, S. K. (1978). The Effectiveness of NEPA. Science (New York, N.Y.), 202(4372), 1038-41. https://doi.org/10.1126/science.202.4372.1038
Fairfax, S K. "The Effectiveness of NEPA." Science (New York, N.Y.) vol. 202,4372 (1978): 1038-41. doi: https://doi.org/10.1126/science.202.4372.1038
Fairfax SK. The Effectiveness of NEPA. Science. 1978 Dec 08;202(4372):1038-41. doi: 10.1126/science.202.4372.1038. PMID: 17777941.
Copy Download .nbib Format: NLM
A disaster in the environmental movement.

Science (New York, N.Y.)

Fairfax SK.
PMID: 17836276
Science. 1978 Feb 17;199(4330):743-8. doi: 10.1126/science.199.4330.743.

No abstract available.

Cite
Fairfax SK. A disaster in the environmental movement. Science. 1978;199(4330):743-8doi: 10.1126/science.199.4330.743.
Fairfax, S. K. (1978). A disaster in the environmental movement. Science (New York, N.Y.), 199(4330), 743-8. https://doi.org/10.1126/science.199.4330.743
Fairfax, S K. "A disaster in the environmental movement." Science (New York, N.Y.) vol. 199,4330 (1978): 743-8. doi: https://doi.org/10.1126/science.199.4330.743
Fairfax SK. A disaster in the environmental movement. Science. 1978 Feb 17;199(4330):743-8. doi: 10.1126/science.199.4330.743. PMID: 17836276.
Copy Download .nbib Format: NLM
Genetic variants associated with non-typhoidal Salmonella bacteraemia in African children.

Lancet (London, England)

Gilchrist JJ, Mills TC, Naranbhai V, Chapman SJ, Fairfax BP, Knight JC, Williams TN, Scott JA, MacLennan CA, Rautanen A, Hill AV.
PMID: 26312835
Lancet. 2015 Feb 26;385:S13. doi: 10.1016/S0140-6736(15)60328-2.

BACKGROUND: Non-typhoidal Salmonella (NTS) causes invasive and frequently fatal disease in African children. Existing strategies to prevent, diagnose, and treat NTS disease are inadequate. An improved understanding of the biology of invasive Salmonella infection will facilitate the development of...

Cite
Gilchrist JJ, Mills TC, Naranbhai V, et al. Genetic variants associated with non-typhoidal Salmonella bacteraemia in African children. Lancet. 2015;385:S13doi: 10.1016/S0140-6736(15)60328-2.
Gilchrist, J. J., Mills, T. C., Naranbhai, V., Chapman, S. J., Fairfax, B. P., Knight, J. C., Williams, T. N., Scott, J. A., MacLennan, C. A., Rautanen, A., Hill, A. V. (2015). Genetic variants associated with non-typhoidal Salmonella bacteraemia in African children. Lancet (London, England), 385S13. https://doi.org/10.1016/S0140-6736(15)60328-2
Gilchrist, James J, et al. "Genetic variants associated with non-typhoidal Salmonella bacteraemia in African children." Lancet (London, England) vol. 385 (2015): S13. doi: https://doi.org/10.1016/S0140-6736(15)60328-2
Gilchrist JJ, Mills TC, Naranbhai V, Chapman SJ, Fairfax BP, Knight JC, Williams TN, Scott JA, MacLennan CA, Rautanen A, Hill AV. Genetic variants associated with non-typhoidal Salmonella bacteraemia in African children. Lancet. 2015 Feb 26;385:S13. doi: 10.1016/S0140-6736(15)60328-2. PMID: 26312835; PMCID: PMC6858854.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries